• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Teleflex Receives FDA 510(k) Clearance of the AC3 Range™ Intra-Aortic Balloon Pump (IABP)

    4/1/25 6:30:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care
    Get the next $TFX alert in real time by email

    WAYNE, Pa., April 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced FDA 510(k) clearance of the AC3 Range™ Intra-Aortic Balloon Pump (IABP). Leveraging the patented technology of the AC3 Optimus™ IABP, the AC3 Range™ IABP is designed to provide reliable, ongoing IABP support across various patient transport modes, including ambulances and both fixed- and rotary-wing aircrafts.

    The AC3 Range™ IABP combines the simple interface and proprietary algorithms of the AC3 Optimus™ IABP to deliver the same precisely timed support1 with features designed specifically for challenges unique to transport, including a full-size helium tank, dual power options, a metal-reinforced extendable handle, and four 360-degree swivel wheels for maneuverability.

    "Cardiac patients with life-threatening hemodynamic instability often present to smaller hospitals yet benefit from care at shock centers," said Dr. Christopher Buller, MD, Medical Director, Teleflex. "Stabilization prior to and during transport is critical, and the AC3 Range™ Intra-Aortic Balloon Pump helps address this need with a compact pump compatible with commonly used ground and air ambulance vehicles."

    "For nearly 40 years, Teleflex has been committed to advancing intra-aortic balloon pumping, delivering cardiac support for critically ill patients," said Roger Graham, President and General Manager, Teleflex Interventional. "With the AC3 Range™ IABP, we extend this commitment across care settings, serving patients throughout their care journey and supporting the health care providers who depend on this technology in the field."

    With the 510(k) clearance, the AC3 Range™ IABP will enter full market release in the United States and will begin shipping to customers in the second quarter of 2025.

    Teleflex will be attending the 45th Annual Meeting & Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT) April 27-30 in Boston, MA. As part of the event, Teleflex will host a lunch symposium exploring the role of IABP therapy in cardiac transplant patients. Attendees can also visit Teleflex booth 623 to see both the AC3 Optimus™ and AC3 Range™ IABPs on display.

    About Teleflex

    As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.

    Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.

    At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.

    Forward-Looking Statements

    Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

    Reference

    1. Donelli A, Jansen JRC, Hoeksel B, et al. Performance of a real-time dicrotic notch detection and prediction algorithm in arrhythmic human aortic pressure signals. J Clin Monit. 2002;17(3-4):181-185. Study sponsored by Teleflex.

    CAUTION: Federal (USA) law restricts these devices for sale or use by or on the order of a physician.

    Teleflex, the Teleflex logo, AC3 Optimus, AC3 Range, Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates in the U.S. and/or other countries. Refer to the Instructions for Use for a complete listing of the indications, contraindications, warnings, and precautions. Information in this document is not a substitute for the product Instructions for Use. Not all products may be available in all countries. Please contact your local representative.

    © 2025 Teleflex Incorporated. All rights reserved. MC-010652 Rev 0.

    Contacts:

    For Teleflex Incorporated:

    Lawrence Keusch

    Vice President, Investor Relations and Strategy Development

    [email protected]

    610.948.2836



    Primary Logo

    Get the next $TFX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TFX

    DatePrice TargetRatingAnalyst
    3/4/2025$235.00 → $140.00Neutral → Underperform
    BofA Securities
    2/28/2025$220.00 → $155.00Outperform → Sector Perform
    RBC Capital Mkts
    2/28/2025Outperform → Mkt Perform
    Raymond James
    2/28/2025$255.00 → $140.00Overweight → Neutral
    Piper Sandler
    2/27/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    7/1/2024$205.00 → $245.00Neutral → Overweight
    Piper Sandler
    12/4/2023$261.00Equal-Weight → Overweight
    Morgan Stanley
    6/21/2023Buy → Hold
    Needham
    More analyst ratings

    $TFX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Teleflex Incorporated

      SC 13G/A - TELEFLEX INC (0000096943) (Subject)

      11/14/24 1:28:29 PM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Teleflex Incorporated

      SC 13G/A - TELEFLEX INC (0000096943) (Subject)

      11/8/24 10:29:30 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Teleflex Incorporated (Amendment)

      SC 13G/A - TELEFLEX INC (0000096943) (Subject)

      2/14/24 10:04:36 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care

    $TFX
    Financials

    Live finance-specific insights

    See more
    • Teleflex Announces Quarterly Dividend

      WAYNE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 16, 2025, to shareholders of record at the close of business on May 20, 2025. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgi

      5/12/25 6:30:00 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Teleflex Reports First Quarter Financial Results and Full Year 2025 Outlook

      WAYNE, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) (the "Company") today announced financial results for the first quarter ended March 30, 2025. First quarter financial summary Revenues of $700.7 million, down 5.0% compared to the prior year period; down 3.8% on an adjusted constant currency basis GAAP diluted EPS from continuing operations of $2.07, compared to $0.33 in the prior year period Adjusted diluted EPS from continuing operations of $2.91, compared to $3.21 in the prior year period 2025 guidance summary Raising GAAP revenue growth guidance range to 1.28% to 2.28% Maintaining adjusted constant currency revenue growth guidan

      5/1/25 6:30:00 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Teleflex Announces First Quarter 2025 Earnings Conference Call Information

      WAYNE, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 1, 2025. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, teleflex.com. An audio replay of the call will be available beginning at 11:00 am Eastern Time on May 1, 2025, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all ot

      4/17/25 6:30:00 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care

    $TFX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $TFX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Teleflex Showcases New Clinical Data Presented at the 2025 American Urological Association (AUA) Annual Meeting

      Two Head-to-Head Randomized Trials Highlight Superior Early Patient Experience with the UroLift™ System for BPH1-2 First-Ever Analysis Utilizing the American Urological Association Quality Registry (AQUA) to Assess BPH Treatment Modalities Shows Strongest Symptom Improvement Score Shift with UroLift™ System at Three Months.3 First Study to Confirm Safety of Stabilized Hyaluronic Acid (sHA) Rectal Spacer in Cases with Rectal Wall Infiltration (RWI).4 WAYNE, Pa., May 15, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a global leader in medical technologies, today announced the presentation of compelling new clinical data at the 2025 American Urological Association (AUA) Annua

      5/15/25 6:30:00 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • New Retrospective Study Reports Significantly Reduced Post-Operative GERD Rates with the Titan SGS™ Stapler from Teleflex Compared with Multi-Fire Staplers in Sleeve Gastrectomy

      Data also demonstrate significantly lower rates of postoperative reflux and decreased incidence of de novo gastroesophageal reflux disease (GERD) without affecting total weight loss at 1-year*, and shorter average hospital length of stay (LOS) associated with use of the Titan SGS™ Stapler compared with multi-fire staplers1 WAYNE, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the publication of a new retrospective analysis of clinical data associating the use of the Titan SGS™ Stapler with reduced rates of post-operative GERD following robotic-assisted laparoscopic sleeve gastrectomy (LSG) compared

      5/13/25 6:30:00 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Teleflex Announces Quarterly Dividend

      WAYNE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 16, 2025, to shareholders of record at the close of business on May 20, 2025. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgi

      5/12/25 6:30:00 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Director Duncan Candace H was granted 1,051 shares, increasing direct ownership by 22% to 5,907 units (SEC Form 4)

      4 - TELEFLEX INC (0000096943) (Issuer)

      5/13/25 5:03:30 PM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Director Patil Neena M was granted 1,051 shares, increasing direct ownership by 67% to 2,626 units (SEC Form 4)

      4 - TELEFLEX INC (0000096943) (Issuer)

      5/13/25 5:03:06 PM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Director Heinmiller John C was granted 1,051 shares, increasing direct ownership by 34% to 4,176 units (SEC Form 4)

      4 - TELEFLEX INC (0000096943) (Issuer)

      5/13/25 5:03:20 PM ET
      $TFX
      Medical/Dental Instruments
      Health Care

    $TFX
    SEC Filings

    See more
    • Teleflex Incorporated filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - TELEFLEX INC (0000096943) (Filer)

      5/15/25 4:06:35 PM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Teleflex Incorporated

      10-Q - TELEFLEX INC (0000096943) (Filer)

      5/1/25 11:49:55 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Teleflex Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - TELEFLEX INC (0000096943) (Filer)

      5/1/25 7:00:52 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care

    $TFX
    Leadership Updates

    Live Leadership Updates

    See more
    • DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

      3/7/25 6:19:00 PM ET
      $ALK
      $AMBC
      $ATI
      $BBWI
      Air Freight/Delivery Services
      Consumer Discretionary
      Property-Casualty Insurers
      Finance
    • Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

      Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With

      3/4/25 11:38:00 AM ET
      $ABT
      $TFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Teleflex Announces Planned Retirement of Thomas Powell As Chief Financial Officer

      WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that Thomas E. Powell, Teleflex's Chief Financial Officer, has decided to retire as Executive Vice President and Chief Financial Officer, effective April 1, 2025. John R. Deren, who currently serves as Corporate Vice President and Chief Accounting Officer of Teleflex, will succeed Mr. Powell as Executive Vice President and Chief Financial Officer, effective April 2, 2025. Following his retirement, Mr. Powell will serve as a consultant to the company through March 31, 2026 to support continuity and a smooth transition. "Tom has announced his des

      2/27/25 6:36:00 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care

    $TFX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Teleflex downgraded by BofA Securities with a new price target

      BofA Securities downgraded Teleflex from Neutral to Underperform and set a new price target of $140.00 from $235.00 previously

      3/4/25 7:44:32 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Teleflex downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded Teleflex from Outperform to Sector Perform and set a new price target of $155.00 from $220.00 previously

      2/28/25 7:34:55 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Teleflex downgraded by Raymond James

      Raymond James downgraded Teleflex from Outperform to Mkt Perform

      2/28/25 7:34:03 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care